Proliferation signal inhibitors: Chemical, biologic, and clinical properties

Transplantation Reviews

Volumn 19, Issue 4, 2005, Pages 186-212

  Lisik, Wojciech ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; COLESEVELAM; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; EZETIMIBE; FENOFIBRATE; FINGOLIMOD; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INITIATION FACTOR 4F; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TEMSIROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ANEMIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTHRALGIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CLINICAL TRIAL; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; EDEMA; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG TOXICITY; LYMPHOCELE; LYMPHOCYTE PROLIFERATION; MOLECULAR MECHANICS; MOLECULAR WEIGHT; MYCOSIS; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW; THROMBOCYTOPENIA; VIRUS INFECTION; WOUND HEALING IMPAIRMENT;

EID: 31644437627     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2005.11.001     Document Type: Review

References (307)

1. C. Vezina A. Kudelski S.N. Sehgal Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J Antibiot (Tokyo) 28 10 1975 721-726
2. S. Sehgal H. Baker C. Vezina Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization J Antibiot (Tokyo) 28 1975 727-732
3. J. Douros M. Suffness New antitumor substances of natural origin Cancer Treat Rev 8 1 1981 63-87
4. C.P. Eng S.N. Sehgal C. Vezina Activity of rapamycin (AY-22,989) against transplanted tumors J Antibiot (Tokyo) 37 10 1984 1231-1237
5. N.L. Paiva A.L. Demain M.F. Roberts Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus J Nat Prod 54 1 1991 167-177
6. I. Segarra, et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin J Chromatogr B Biomed Sci Appl 720 1-2 1998 179-187
7. M.W. Harding Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy Clin Cancer Res 9 8 2003 2882-2886
8. R. Woodroffe, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study Health Technol Assess 9 21 2005 1-194
9. M.A. Bjornsti P.J. Houghton The TOR pathway: A target for cancer therapy Nat Rev Cancer 4 5 2004 335-348
10. G. Ferguson I. Mothe-Satney J.C. Lawrence Jr. Ser-64 and Ser-111 in PHAS-I are dispensable for insulin-stimulated dissociation from eIF4E J Biol Chem 278 48 2003 47459-47465
11. W.A. Walters, et al. Antenatal diagnosis of thalassemia Med J Aust 146 4 1987 226
12. M.J. Staruch N.H. Sigal F.J. Dumont Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis Int J Immunopharmacol 13 6 1991 677-685
13. K. Yonezawa, et al. Raptor, a binding partner of target of rapamycin Biochem Biophys Res Commun 313 2 2004 437-441
14. D. Barford A.J. Flint N.K. Tonks Crystal structure of human protein tyrosine phosphatase 1B Science 263 5152 1994 1397-1404
15. C.M. Alarcon J. Heitman M.E. Cardenas Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast Mol Biol Cell 10 8 1999 2531-2546
16. E. Jacinto M.N. Hall TOR signalling in bugs, brain and brawn Nat Rev Mol Cell Biol 4 2 2003 117-126
17. C.G. Proud mTOR-mediated regulation of translation factors by amino acids Biochem Biophys Res Commun 313 2 2004 429-436
18. T. Pawson Signal transduction. Look at a tyrosine kinase Nature 372 6508 1994 726-727
19. M. Abe A.W. Thomson Influence of immunosuppressive drugs on dendritic cells Transpl Immunol 11 3-4 2003 357-365
20. S. Caldarola, et al. Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events J Biol Chem 279 14 2004 13522-13531
21. A. Beugnet X. Wang C.G. Proud Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1 J Biol Chem 278 42 2003 40717-40722
22. A.S. Kristof, et al. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin J Biol Chem 278 36 2003 33637-33644
23. S. Gupta, et al. Transcription factor ATF2 regulation by the JNK signal transduction pathway Science 267 5196 1995 389-393
24. A.L. Edinger, et al. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells Cancer Res 63 23 2003 8451-8460
25. B.D. Manning L.C. Cantley United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling Biochem Soc Trans 31 Pt 3 2003 573-578
26. B. Geoerger, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 4 2001 1527-1532
27. M.A. Gallicchio M. van Sinderen L.A. Bach Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth Horm Metab Res 35 11-12 2003 822-827
28. L.A. Feig B. Schaffhausen Signal transduction. The hunt for Ras targets Nature 370 6490 1994 508-509
29. A. Boulay, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res 64 1 2004 252-261
30. X. Gao, et al TSC tumour suppressor proteins antagonize amino-acid-TOR signalling Nat Cell Biol 4 9 2002 699-704
31. K. Inoki, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 9 2002 648-657
32. C.J. Potter L.G. Pedraza T. Xu Akt regulates growth by directly phosphorylating TSC2 Nat Cell Biol 4 9 2002 658-665
33. L.S. Jefferson S.R. Kimball Amino acids as regulators of gene expression at the level of mRNA translation J Nutr 133 6 Suppl 1 2003 2046S-2051S
34. T. Stromberg, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood 103 8 2004 3138-3147
35. C. Tokunaga K. Yoshino K. Yonezawa mTOR integrates amino acid- and energy-sensing pathways Biochem Biophys Res Commun 313 2 2004 443-446
36. D.H. Kim, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol Cell 11 4 2003 895-904
37. C. Koch, et al. A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase Science 261 5128 1993 1551-1557
38. N. Oshiro, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function Genes Cells 9 4 2004 359-366
39. K. Yonezawa, et al. Kinase activities associated with mTOR Curr Top Microbiol Immunol 279 2004 271-282
40. C. Mayer, et al. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability Genes Dev 18 4 2004 423-434
41. K. Takeya T. Otohuji H. Tokiwa FK phage for differentiating the classical and El T or groups of Vibrio cholerae J Clin Microbiol 14 2 1981 222-224
42. J.M. Suh, et al. Regulation of the phosphatidylinositol 3-kinase, Akt/ protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland J Biol Chem 278 24 2003 21960-21971
43. F. Lekmine, et al. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein Exp Cell Res 295 1 2004 173-182
44. A.P. Tabancay Jr., et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K J Biol Chem 278 41 2003 39921-39930
45. J.E. Kim J. Chen Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation Proc Natl Acad Sci U S A 97 26 2000 14340-14345
46. S.N. Sehgal Sirolimus: Its discovery, biological properties, and mechanism of action Transplant Proc 35 3 Suppl 2003 7S-14S
47. M. Gstaiger, et al. Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI Science 302 5648 2003 1208-1212
48. J. Zhu E.D. Spencer R.L. Kaspar Differential translation of TOP mRNAs in rapamycin-treated human B lymphocytes Biochim Biophys Acta 1628 1 2003 50-55
49. S.J. Swanson, et al. A Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy Lancet 360 9346 2002 1662-1664
50. S.J. Tang, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus Proc Natl Acad Sci U S A 99 1 2002 467-472
51. F. Lekmine, et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons J Biol Chem 278 30 2003 27772-27780
52. G.J. Browne C.G. Proud A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin Mol Cell Biol 24 7 2004 2986-2997
53. R.M. Drenan, et al. FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus J Biol Chem 279 1 2004 772-778
54. B.J. Andrews S.W. Mason Gene expression and the cell cycle: A family affair Science 261 5128 1993 1543-1544
55. J.R. Peters, et al. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin Am J Cardiol 71 16 1993 1485-1488
56. F. Pages, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling Nature 369 6478 1994 327-329
57. G.W. Byrne, et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function Am J Transplant 5 5 2005 1011-1020
58. H. Chen, et al. Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat Transplantation 59 8 1995 1084-1089
59. H. Asao, et al. Interleukin 2 (IL-2)-induced tyrosine phosphorylation of IL-2 receptor p75 J Exp Med 171 3 1990 637-644
60. J.L. Sanchez, et al. Protective efficacy of oral whole-cell/ recombinant-B-subunit cholera vaccine in Peruvian military recruits Lancet 344 8932 1994 1273-1276
61. M. Kondo, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4 Science 262 5141 1993 1874-1877
62. A. Khanna, et al. Mechanism of action of cyclosporine: A new hypothesis implicating transforming growth factor-beta Transplant Rev 9 1995 41-48
63. Y. Prashar, et al. Stimulation of transforming growth factor-beta 1 transcription by cyclosporine FEBS Lett 358 2 1995 109-112
64. T.M. Kundig, et al. Immune responses in interleukin-2-deficient mice Science 262 5136 1993 1059-1061
65. X. Fenghao, et al. Interleukin 4 activates a signal transducer and activator of transcription (Stat) protein which interacts with an interferon-gamma activation site-like sequence upstream of the I epsilon exon in a human B cell line. Evidence for the involvement of Janus kinase 3 and interleukin-4 Stat J Clin Invest 96 2 1995 907-914
66. A. Heredia, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1 Proc Natl Acad Sci U S A 100 18 2003 10411-10416
67. T. Tamura T. Yanagida H. Nariuchi Difference in signal transduction pathway for IL-2 and IL-4 production in T helper 1 and T helper 2 cell clones in response to anti-CD3 J Immunol 151 11 1993 6051-6061
68. J. Hou, et al. An interleukin-4-induced transcription factor: IL-4 Stat Science 265 5179 1994 1701-1706
69. S. Koyasu The role of PI3K in immune cells Nat Immunol 4 4 2003 313-319
70. K. Okkenhaug B. Vanhaesebroeck PI3K in lymphocyte development, differentiation and activation Nat Rev Immunol 3 4 2003 317-330
71. J.A. Deane D.A. Fruman Phosphoinositide 3-kinase: Diverse roles in immune cell activation Annu Rev Immunol 22 2004 563-598
72. M. Rothe, et al. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 Science 269 5229 1995 1424-1427
73. Y.J. Jung, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis J. Faseb 17 14 2003 2115-2117
74. Q. Zhang, et al. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia Leuk Res 23 4 1999 373-384
75. B. Kaplan, et al. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve Clin Chem 43 3 1997 539-540
76. P.A. Steck, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet 15 4 1997 356-362
77. D.J. Marsh, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome Hum Mol Genet 8 8 1999 1461-1472
78. S.H. Yang A.J. Dickson Inhibitors of signalling identify differential control processes responsible for selective effects of insulin on the expression of phosphoenolpyruvate carboxykinase and gene 33 in rat H4 hepatoma cells J. Biochem 310 Pt 2 1995 375-378
79. A. Aguilera, et al. Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells Int J Artif Organs 28 2 2005 164-169
80. S.R. Datta, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 2 1997 231-241
81. O. Jimenez, et al. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation Transplant Proc 35 5 2003 1686-1688
82. B.K. Kramer, et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab Transplant Proc 37 3 2005 1601-1604
83. A. Agarwal, et al. The AKT/I kappa B kinase pathway promotes angiogenic/ metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin Oncogene 24 6 2005 1021-1031
84. J.A. Gustin, et al. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation J Biol Chem 279 3 2004 1615-1620
85. Z.L. Chu, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control Proc Natl Acad Sci U S A 94 19 1997 10057-10062
86. S. Huang, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1) Mol Cell 11 6 2003 1491-1501
87. J. Choi, et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273 5272 1996 239-242 Science
88. J. Marx Taking a first look at a tyrosine phosphatase Science 263 5152 1994 1373
89. P.D. Jeffrey, et al. Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex Nature 376 6538 1995 313-320
90. G.J. Brunn, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin Science 277 5322 1997 99-101
91. W.M. Flanagan G.R. Crabtree Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition Ann N Y Acad Sci 696 1993 31-37
92. J.H. Lai T.H. Tan CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin J Biol Chem 269 48 1994 30077-30080
93. M. Pagano, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 269 5224 1995 682-685
94. S. Vignot, et al. mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 4 2005 525-537
95. R.Y. Calne, et al. Rapamycin for immunosuppression in organ allografting Lancet 2 8656 1989 227
96. R.E. Morris J. Wu R. Shorthouse A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection Transplant Proc 22 4 1990 1638-1641
97. R.E. Morris B. Meiser Identification of a new pharmacologic action for an old compound Med Sci Res 17 1989 609-610
98. S.M. Stepkowski, et al. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat Transplantation 51 1 1991 22-26
99. S.M. Stepkowski, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection Clin Exp Immunol 108 1 1997 63-68
100. S.M. Stepkowski Sirolimus, a potent new immunosuppressive drug for organ transplantation Ann Transplant 1 3 1996 19-25
101. S.M. Stepkowski, et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats Transplantation 62 7 1996 986-994
102. S.M. Stepkowski, et al. Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin Transplantation 53 2 1992 258-264
103. M. Wang, et al. Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus Transplantation 61 3 1996 458-464
104. S.M. Stepkowski B.D. Kahan Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival Transplant Proc 23 6 1991 3262-3264
105. K.L. Napoli, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions Ther Drug Monit 20 2 1998 123-133
106. S.M. Stepkowski, et al. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival Transplant Proc 30 5 1998 2214-2216
107. M.E. Wang, et al. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus Transplantation 65 7 1998 899-905
108. D.S. Collier, et al. Rapamycin in experimental renal allografts in dogs and pigs Transplant Proc 22 4 1990 1674-1675
109. T. Ochiai, et al. Effects of rapamycin in experimental organ allografting Transplantation 56 1 1993 15-19
110. D.K. Granger, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy Transplantation 59 2 1995 183-186
111. R. Knight, et al. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model Transplantation 55 4 1993 947-949
112. H. Chen, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus Transplantation 69 8 2000 1555-1561
113. B. Hausen, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin Transplantation 69 4 2000 488-496
114. B. Hausen, et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability Transplantation 69 1 2000 76-86
115. Kahan BD. [unpublished]
116. M.G. Murgia S. Jordan B.D. Kahan The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients Kidney Int 49 1 1996 209-216
117. J.J. Zimmerman B.D. Kahan Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration J Clin Pharmacol 37 5 1997 405-415
118. B.D. Kahan, et al. Immunosuppressive effects and safety of a sirolimus/ cyclosporine combination regimen for renal transplantation Transplantation 66 8 1998 1040-1046
119. B.D. Kahan Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group Lancet 356 9225 2000 194-202
120. A. Lindholm, et al. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss Transplantation 55 5 1993 985-993
121. A.O. Gaber, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 66 1 1998 29-37
122. J.F. Neylan Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group Transplantation 64 9 1997 1277-1282
123. C.G. Groth, et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group Transplantation 67 7 1999 1036-1042
124. H. Kreism, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients Transplantation 69 7 2000 1252-1260
125. J.M. Morales, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients Am J Transplant 2 5 2002 436-442
126. B.D. Kahan, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group Transplantation 68 10 1999 1526-1532
127. A.S. MacDonald A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2 2001 271-280
128. B.D. Kahan W.G. Kramer Median effect analysis of efficacy versus adverse effects of immunosuppressants Clin Pharmacol Ther 70 1 2001 74-81
129. R.W. Johnson, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 5 2001 777-786
130. R. Oberbauer, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study Transplantation 76 2 2003 364-370
131. C. Legendre, et al. Early cyclosporine withdrawal with sirolimus maintenance therapy in presence of risk factors for reduced renal function: 5-year results from the Rapamune maintenance regimen (RMR) trial ESOT 2005 [abstract OR-119]
132. B.D. Kahan Toward calcineurin antagonist minimization Transplantation 77 1 2004 162 [author reply 162-3]
133. V. Bumbea, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 2005 2517-2523
134. B.D. Kahan, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 3 2002 330-350
135. B.D. Kahan, et al. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection Transplantation 71 10 2001 1400-1406
136. J.M. Kovarik, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range Transplantation 73 6 2002 920-925
137. E.S. Woodle, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus Am J Transplant 5 1 2005 157-166
138. S. Vitko, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 4 2004 626-635
139. B.D. Kahan The role of rapamycin in chronic rejection prophylaxis: A theoretical consideration Graft 1 2 Suppl II 1998 93-96
140. A. Keogh, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial Circulation 110 17 2004 2694-2700
141. P.N. Ruygrok, et al. Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression J Heart Lung Transplant 22 11 2003 1276-1279
142. J. Groetzner, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure Transplantation 77 4 2004 568-574
143. H.J. Eisen, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 9 2003 847-858
144. B. Cahill, et al. Early experience with sirolimus in lung transplant recipients J Heart Lung Transplant 20 2 2001 162
145. J. Fung, et al. Immunosuppression in liver transplantation: Beyond calcineurin inhibitors Liver Transpl 11 3 2005 267-280
146. Wyeth, http://www.wyeth.com/news/Pressed_and_Released/ pr06_11_2004_09_46_10.asp?archive=2004.
147. J.F. Trotter Sirolimus in liver transplantation Transplant Proc 35 3 Suppl 2003 193S-200S
148. J.C. Dunkelberg, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications Liver Transpl 9 5 2003 463-468
149. V.C. McAlister, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus Liver Transpl 7 8 2001 701-708
150. K.D. Fairbanks, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 10 2003 1079-1085
151. B. Forgacs, et al. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation Transplant Proc 37 4 2005 1912-1914
152. M. Markiewicz, et al. Rapamycin in children after liver transplantation Transplant Proc 35 6 2003 2284-2286
153. V.D. Garcia, et al. Immunosuppression in pancreas transplantation: mycophenolate mofetil versus sirolimus Transplant Proc 36 4 2004 975-977
154. D.B. Kaufman, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: Comparison of two maintenance immunosuppression protocols: Tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus Transplantation 73 2 2002 169-177
155. R.J. Knight, et al. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine Transplant Proc 37 2 2005 1280-1282
156. A. Salazar, et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: Effect on renal function Transplant Proc 33 1-2 2001 1038-1039
157. J.M. Morales Cardiovascular risk profile in patients treated with sirolimus after renal transplantation Kidney Int Suppl (93) 2005 S69-S73
158. A.J. Collins, et al. Excerpts from the United States Renal Data System 2004 annual data report: Atlas of end-stage renal disease in the United States Am J Kidney Dis 45 1 Suppl 1 2005 A5-A7
159. B.L. Kasiske Cardiovascular disease after renal transplantation Semin Nephrol 20 2 2000 176-187
160. R.N. Foley P.S. Parfrey M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 5 Suppl 3 1998 S112-S119
161. S.C. Chueh B.D. Kahan Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis Transplantation 76 2 2003 375-382
162. J.D. Morrisett G. Abdel-Fattah B.D. Kahan Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients Transplant Proc 35 3 Suppl 2003 143S-150S
163. B.D. Kahan Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation Transplant Proc 35 3 Suppl 2003 37S-51S
164. R.J. Firpi, et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent Aliment Pharmacol Ther 19 9 2004 1033-1039
165. R.N. Formica Jr., et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation Transplant Proc 35 3 Suppl 2003 95S-98S
166. R.C. Hoogeveen, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients Transplantation 72 7 2001 1244-1250
167. M.D. Tur, et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: Implications in transplantation-induced dyslipidemia Transplant Proc 32 8 2000 2783-2784
168. C.B. Blum Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model Am J Transplant 2 6 2002 551-559
169. D.E. Hricik, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus Transplantation 76 6 2003 938-942
170. G.R. Russ, et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients Transplant Proc 35 3 Suppl 2003 115S-117S
171. V.C. McAlister, et al. Sirolimus-tacrolimus combination immunosuppression Lancet 355 9201 2000 376-377
172. A.S. MacDonald Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation Transplant Proc 35 3 Suppl 2003 201S-208S
173. B.D. Kahan, et al. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience Transplant Proc 35 3 Suppl 2003 25S-34S
174. J.W. Moses, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 14 2003 1315-1323
175. M. Poon J.J. Badimon V. Fuster Overcoming restenosis with sirolimus: from alphabet soup to clinical reality Lancet 359 9306 2002 619-622
176. J.A. Kobashigawa Statins in solid organ transplantation: Is there an immunosuppressive effect? Am J Transplant 4 7 2004 1013-1018
177. W. Lisik, et al. The beneficial effect of co-administration of statins on the outcomes of renal transplant recipients treated with a sirolimus-cyclosporine regimen Transplantation 2005 [in press]
178. J.M. Kovarik, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus J Clin Pharmacol 42 2 2002 222-228
179. P.W. Pflugfelder, et al. Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial J Heart Lung Transplant 14 4 1995 613-622
180. D.D. Stapleton, et al. Lipid-lowering therapy and long-term survival in heart transplantation Am J Cardiol 80 6 1997 802-805
181. N. Marx, et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis Circ Res 90 6 2002 703-710
182. K. Nakayama, et al. Requirement for CD8 beta chain in positive selection of CD8-lineage T cells Science 263 5150 1994 1131-1133
183. D. Lan D.L. Silver Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1 J Biol Chem 280 24 2005 23390-23396
184. L.E. Gustavson, et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3{alpha}-hydroxy isomeric metabolite J Clin Pharmacol 45 8 2005 947-953
185. S. Morris R. Tiller Ezetimibe for hypercholesterolemia Am Fam Physician 68 8 2003 1595-1596
186. M.H. Davidson Ezetimibe: A novel option for lowering cholesterol Expert Rev Cardiovasc Ther 1 1 2003 11-21
187. J.J. Puthenparumpil, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population Transplant Proc 37 2 2005 1033-1035
188. J.M. McKenney Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks Am J Cardiol 96 4A 2005 60-66
189. K.L. Steinmetz K.S. Schonder Colesevelam: Potential uses for the newest bile resin Cardiovasc Drug Rev 23 1 2005 15-30
190. J.C. Hong B.D. Kahan Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management Transplantation 69 10 2000 2085-2090
191. J.M. Kovarik, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure J Heart Lung Transplant 22 10 2003 1117-1125
192. J.J. Augustine, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients Am J Transplant 4 12 2004 2001-2006
193. A.O. Morla, et al. Hematopoietic growth factors activate the tyrosine phosphorylation of distinct sets of proteins in interleukin-3-dependent murine cell lines Mol Cell Biol 8 5 1988 2214-2218
194. P.A. Helliwell M.G. Rumsby G.L. Kellett Intestinal sugar absorption is regulated by phosphorylation and turnover of protein kinase C betaII mediated by phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent pathways J Biol Chem 278 31 2003 28644-28650
195. S. Nagarajan, et al. Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus Pediatr Transplant 9 1 2005 97-100
196. S.M. Flechner, et al. The effect of 2-gram versus 1-gram concentration
197. E.M. Vasquez Sirolimus: A new agent for prevention of renal allograft rejection Am J Health Syst Pharm 57 5 2000 437-448
198. A.K. Sundberg, et al. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients Clin Transplant 18 Suppl 12 2004 61-66
199. S. Hanabuchi, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity Proc Natl Acad Sci U S A 91 11 1994 4930-4934
200. K. Migita, et al. Effects of rapamycin on apoptosis of rheumatoid synovial cells Clin Exp Immunol 108 2 1997 199-203
201. E. Mahe, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy Transplantation 79 4 2005 476-482
202. M.G. Mohaupt B. Vogt F.J. Frey Sirolimus-associated eyelid edema in kidney transplant recipients Transplantation 72 1 2001 162-164
203. H. Wadei, et al. Sirolimus-induced angioedema Am J Transplant 4 6 2004 1002-1005
204. H. Kreis, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal J Am Soc Nephrol 15 3 2004 809-817
205. C. Benavides, et al. Rabbit antithymocyte globulin: A postoperative risk factor for sirolimus-treated renal transplant patients? Transplant Proc 37 2 2005 822-826
206. I.H. Derweesh, et al. Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression on early functional recovery of kidney transplants AST 73 2005
207. R.M. Langer B.D. Kahan Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients Transplantation 74 6 2002 804-808
208. J.R. Chapman Optimizing the long-term outcome of renal transplants: opportunities created by sirolimus Transplant Proc 35 3 Suppl 2003 67S-72S
209. J.R. Chapman J.P. O'Connell B.J. Nankivell Chronic renal allograft dysfunction J Am Soc Nephrol 16 10 2005 3015-3026
210. B.D. Kahan J.S. Camardo Rapamycin: Clinical results and future opportunities Transplantation 72 7 2001 1181-1193
211. H. Podder, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations J Am Soc Nephrol 12 5 2001 1059-1071
212. P. Kelly B.D. Kahan Review: Metabolism of immunosuppressant drugs Curr Drug Metab 3 3 2002 275-287
213. T. Gonwa, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months Transplantation 75 8 2003 1213-1220
214. C.B. Hodges, et al. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity Pediatr Nephrol 16 10 2001 777-778
215. J.M. Morales, et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation Transplant Proc 35 3 Suppl 2003 154S-156S
216. W. Lieberthal Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells Am J Physiol Renal Physiol 281 4 2001 F693-F706
217. A. Lo, et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation Clin Transplant 18 1 2004 53-61
218. C. Davis Sirolimus delays renal allograft recovery Am J Transplant 3 4 2003 363-365
219. R.A. McTaggart, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation Am J Transplant 3 4 2003 416-423
220. R.J. Knight, et al. Five-year follow-up after prednisone withdrawal using sirolimus-cyclosporine immunosuppression for renal transplantation Am J Transplant 4 2004 300 [abstact 516]
221. K.C. Abbott, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States Transplantation 79 3 2005 330-336
222. R.J. Knight, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function Transplantation 78 6 2004 904-910
223. B.D. Kahan, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation Transplantation 53 2 1992 345-351
224. E. Morelon, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients Transplantation 72 5 2001 787-790
225. S.F. Chen Y.J. Chiang C.C. Huang Sirolimus-induced interstitial pneumonitis in a renal transplant recipient J Formos Med Assoc 102 8 2003 570-573
226. A.A. Haydar, et al. Sirolimus-induced pneumonitis: Three cases and a review of the literature Am J Transplant 4 1 2004 137-139
227. P.T. Pham, et al. Sirolimus-associated pulmonary toxicity Transplantation 77 8 2004 1215-1220
228. B.D. Kahan, et al. The development of sirolimus: The University of Texas-Houston experience Clin Transpl 2000 145-158
229. K.L. Napoli B.D. Kahan Routine clinical monitoring of sirolimus (Rapamycin) whole-blood concentrations by HPLC with ultraviolet detection Clin Chem 42 12 1996 1943-1948
230. U. Christians, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants J Chromatogr B Biomed Sci Appl 748 1 2000 41-53
231. B.D. Kahan, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity Clin Transplant 14 2 2000 97-109
232. D.W. Holt, et al. A microparticle enzyme immunoassay to measure sirolimus Transplant Proc 37 1 2005 182-184
233. K.L. Napoli, et al. Distribution of sirolimus in rat tissue Clin Biochem 30 2 1997 135-142
234. R.W. Yatscoff, et al. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations Ther Drug Monit 17 6 1995 666-671
235. H.E. Wilczek C. Brattstrom Sirolimus experience at a Swedish transplantation center Transplant Proc 35 3 Suppl 2003 84S-88S
236. R. El-Sabrout, et al. Improved freedom from rejection after a loading dose of sirolimus Transplantation 75 1 2003 86-90
237. B.D. Kahan K.L. Napoli Role of therapeutic drug monitoring of rapamycin Transplant Proc 30 5 1998 2189-2191
238. U. Christians, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin Drug Metab Dispos 20 2 1992 186-191
239. J.M. Kovarik, et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation Am J Transplant 3 5 2003 606-613
240. W. Jacobsen, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD Transplant Proc 33 1-2 2001 514-515
241. G.I. Kirchner I. Meier-Wiedenbach M.P. Manns Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 2 2004 83-95
242. J.M. Kovarik, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications Clin Pharmacol Ther 70 3 2001 247-254
243. M. Burdese, et al. Sirolimus and ACE-inhibitors: A note of caution Transplantation 79 2 2005 251-252
244. J.J. Zimmerman Exposure-response relationships and drug interactions of sirolimus AAPS J 6 4 2004 e28
245. D.Y. Gomez, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine Clin Pharmacol Ther 58 1 1995 15-19
246. D.R. Kuypers, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient Transplantation 79 6 2005 737
247. S.M. Flechner, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine Transplantation 74 8 2002 1070-1076
248. B. Kaplan, et al. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent Clin Pharmacol Ther 63 1 1998 48-53
249. B.D. Kahan, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients Transplantation 68 8 1999 1100-1106
250. F.J. Dumont, et al. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes J Pharmacol Exp Ther 268 1 1994 32-41
251. F.J. Dumont, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin J Exp Med 176 3 1992 751-760
252. V.C. McAlister, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration Ther Drug Monit 24 3 2002 346-350
253. N.A. Undre Pharmacokinetics of tacrolimus-based combination therapies Nephrol Dial Transplant 18 Suppl 1 2003 i12-i15
254. W. El Haggan, et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine Transplant Proc 37 2 2005 864-866
255. B.L. Kasiske, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation J Am Soc Nephrol 11 10 2000 1910-1917
256. S.R. Smith, et al. Late withdrawal of cyclosporine in stable renal transplant recipients Am J Kidney Dis 26 3 1995 487-494
257. G. Ciancio, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year Transplantation 77 2 2004 244-251
258. J.P. van Hooff, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients Transplantation 75 12 2003 1934-1939
259. A. Lo, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation Transplantation 77 8 2004 1228-1235
260. B. Nashan, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study Transplantation 78 9 2004 1332-1340
261. A.H. Tejani, et al. Predictive factors for delayed graft function (DGF) and its impact on renal graft survival in children: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Pediatr Transplant 3 4 1999 293-300
262. J.C. Hong B.D. Kahan Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression Transplantation 68 5 1999 701-704
263. J.C. Hong B.D. Kahan A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function Transplantation 71 9 2001 1320-1328
264. R.M. Langer, et al. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors Transplant Proc 34 8 2002 3162-3164
265. T.A. Gonwa, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination Transplantation 74 11 2002 1560-1567
266. A. Mulay, et al. Does conversion from a calcineurin inhibitor to sirolimus improve renal function in allograft nephropathy: A systematic review of the evidence ATC 2005 [abstract 1199]
267. A. Jardine Phase III prospective, randomized study to evaluate the safety and efficacy of Concentration controlled Rapamune (sirolimus) with cyclosporine dose minimisation or elimination in de novo renal allograft recipients at 12 months ATC Boston 2004 [abstract 464]
268. V.R. Peddi, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency Clin Transplant 19 1 2005 130-136
269. A.V. Mulay, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials Am J Transplant 5 7 2005 1748-1756
270. R. Oberbauer, et al. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: Results of a 2-year randomized clinical trial Transplantation 75 8 2003 1277-1285
271. K. Baboolal A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients Transplantation 75 8 2003 1404-1408
272. A.G. Jardine Phase III prospective randomized study to evaluate the safety and efficacy of concentration controlled Rapamune (sirolimus) with cyclosporine dose minimisation or elimination in de novo renal allograft recipients at 12 months Am J Transplant 4 Suppl 8 2004 286 [abstract]
273. G. Stallone, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients Transplantation 75 7 2003 998-1003
274. J.M. Grinyo, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation Am J Transplant 4 8 2004 1308-1314
275. F. Vincenti, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation Transplantation 71 9 2001 1282-1287
276. B. Kaplan, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function Am J Transplant 4 10 2004 1709-1712
277. M.D. Stegall, et al. Kidney transplantation without calcineurin inhibitors using sirolimus Transplant Proc 35 3 Suppl 2003 125S-127S
278. R. Ferguson FTY720 immunomodulation: Optimism for improved transplant regimens Transplant Proc 36 2 Suppl 2004 549S-553S
279. V. Brinkmann J.G. Cyster T. Hla FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function Am J Transplant 4 7 2004 1019-1025
280. P. Troncoso, et al. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine Transplantation 67 1 1999 145-151
281. Z. Nikolova, et al. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD Transpl Immunol 8 2 2000 115-124
282. D.E. Hricik, et al. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients Clin Transplant 9 5 1995 419-423
283. K. Mahalati B.D. Kahan Sirolimus permits steroid withdrawal from a cyclosporine regimen Transplant Proc 33 1-2 2001 1270
284. D.E. Hricik, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids Transplantation 74 2 2002 189-193
285. R. Kandaswamy A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis Am J Transplant 5 6 2005 1529-1536
286. F. Citterio, et al. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid Transplant Proc 37 2 2005 827-829
287. H. Podder, et al. Sirolimus improves the two-year outcome of renal allografts in African-American patients Transpl Int 14 3 2001 135-142
288. J. Gomez-Cambronero Rapamycin inhibits GM-CSF-induced neutrophil migration FEBS Lett 550 1-3 2003 94-100
289. I. Gee, et al. Sirolimus inhibits oxidative burst activity in transplant recipients Transplantation 76 12 2003 1766-1768
290. J.H. Hanke L.N. Nichols M.E. Coon FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA Lymphokine Cytokine Res 11 5 1992 221-231
291. P.G. Machado, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination Clin Transplant 18 1 2004 28-38
292. J.F. Trotter A. Wallack T. Steinberg Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper Transpl Infect Dis 5 4 2003 174-180
293. M.S. Kumar, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients Kidney Int 67 4 2005 1622-1629
294. O. Thaunat, et al. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy Transpl Infect Dis 6 4 2004 179-182
295. S. Muthukkumar T.M. Ramesh S. Bondada Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells Transplantation 60 3 1995 264-270
296. J.M. Campistol A. Gutierrez-Dalmau J.V. Torregrosa Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma Transplantation 77 5 2004 760-762
297. G. Stallone, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 13 2005 1317-1323
298. B.D. Kahan, et al. Low incidence of malignancy among sirolimus/ cyclosporine-treated renal transplant recipient Transplantation 80 2005 749-758
299. T. Mathew H. Kreis P. Friend Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies Clin Transplant 18 4 2004 446-449
300. H.M. Kauffman, et al. Maintenance immunosuppression with TOR inhibitors is associated with a reduced incidence of de novo malignancies 80 2005 883-889
301. T. Hunter Signal transduction. Cytokine connections Nature 366 6451 1993 114-116
302. N.N. Danial A. Pernis P.B. Rothman Jak-STAT signaling induced by the v-abl oncogene Science 269 5232 1995 1875-1877
303. H. Podder B.D. Kahan Janus kinase 3: A novel target for selective transplant immunosuppression Expert Opin Ther Targets 8 6 2004 613-629
304. S.M. Stepkowski, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin Blood 99 2 2002 680-689
305. D.C. Borie J.J. O'Shea P.S. Changelian JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants Trends Mol Med 10 11 2004 532-541
306. D.C. Thomis, et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3 Science 270 5237 1995 794-797
307. M.D. Saemann, et al. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154 Transplantation 75 11 2003 1864-1872